5WBZ

Structure of human Ketohexokinase complexed with hits from fragment screening


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.214 
  • R-Value Work: 0.189 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK).

Huard, K.Ahn, K.Amor, P.Beebe, D.A.Borzilleri, K.A.Chrunyk, B.A.Coffey, S.B.Cong, Y.Conn, E.L.Culp, J.S.Dowling, M.S.Gorgoglione, M.F.Gutierrez, J.A.Knafels, J.D.Lachapelle, E.A.Pandit, J.Parris, K.D.Perez, S.Pfefferkorn, J.A.Price, D.A.Raymer, B.Ross, T.T.Shavnya, A.Smith, A.C.Subashi, T.A.Tesz, G.J.Thuma, B.A.Tu, M.Weaver, J.D.Weng, Y.Withka, J.M.Xing, G.Magee, T.V.

(2017) J. Med. Chem. 60: 7835-7849

  • DOI: 10.1021/acs.jmedchem.7b00947
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, i ...

    Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to further elucidate the effect of KHK inhibition on these metabolic disorders. Until now, studies on KHK inhibition with small molecules have been limited due to the lack of viable in vivo pharmacological tools. Herein we report the discovery of 12, a selective KHK inhibitor with potency and properties suitable for evaluating KHK inhibition in rat models. Key structural features interacting with KHK were discovered through fragment-based screening and subsequent optimization using structure-based drug design, and parallel medicinal chemistry led to the identification of pyridine 12.


    Organizational Affiliation

    Medicine Design, Pfizer Inc. , 1 Portland Street, Cambridge, Massachusetts 02139, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Ketohexokinase
A, B
313Homo sapiensMutation(s): 0 
Gene Names: KHK
EC: 2.7.1.3
Find proteins for P50053 (Homo sapiens)
Go to Gene View: KHK
Go to UniProtKB:  P50053
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
CIT
Query on CIT

Download SDF File 
Download CCD File 
A, B
CITRIC ACID
C6 H8 O7
KRKNYBCHXYNGOX-UHFFFAOYSA-N
 Ligand Interaction
SO4
Query on SO4

Download SDF File 
Download CCD File 
A, B
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
A4J
Query on A4J

Download SDF File 
Download CCD File 
A, B
6-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]-2-[(3S)-3-hydroxy-3-methylpyrrolidin-1-yl]-4-(trifluoromethyl)pyridine-3-carbonitrile
C16 H19 F3 N4 O3
FAXXYODRCHXHTQ-HUBLWGQQSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.214 
  • R-Value Work: 0.189 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 83.180α = 90.00
b = 86.380β = 90.00
c = 137.620γ = 90.00
Software Package:
Software NamePurpose
SCALAdata scaling
BUSTERphasing
BUSTERrefinement
XDSdata reduction
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2017-06-29 
  • Released Date: 2017-09-13 
  • Deposition Author(s): Pandit, J.

Revision History 

  • Version 1.0: 2017-09-13
    Type: Initial release
  • Version 1.1: 2017-10-11
    Type: Database references